KOSPIApparel & Living090370

Metalabs

₩1,029▼ 0.77%2026-11-18 close
Market Cap
₩28.1B
Turnover
₩200M
Volume
170K
Shares out.
27.3M
PER
—
PBR
0.3×
EPS
-₩211
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Metalabs: Quarterly Turnaround, Full-Year Proof Pending

Metalabs swung to quarterly operating profit in Q1 and Q3 2026, but operating losses ran through 2025 and attributable net results still alternate by quarter, so the trend is not yet confirmed.

  1. 1

    Revenue reached KRW 81.3 billion in 2025, up 112.0% year on year, and rose two years in a row from 2024 through 2025.

  2. 2

    Operating losses ran four years in a row from 2022 through 2025, and the KRW 7.24 billion loss in 2025 was larger than the year before.

  3. 3

    Q3 2026 revenue was KRW 40.7 billion, up 35.7% year on year, and operating profit of KRW 1.67 billion turned positive from a loss a year earlier.

  4. 4

    Attributable net income for Q3 2026 was KRW 367 million, yet the last four quarters total an attributable net loss of KRW 5.77 billion.

  5. 5

    The price-to-book ratio sits well below 1x, while earnings-based multiples cannot be calculated, so comparison rests on book value.

02

Business structure

Metalabs runs two main businesses: fashion and hair-loss medical management services (MSO). The fashion segment centers on licensing and vendor operations for premium luxury brands, and a business launched in June 2025 has driven growth.

According to the company, that business alone generated KRW 34.4 billion in revenue in the first half of 2026, when consolidated revenue was KRW 58.0 billion. Distribution depends on TV home shopping and live commerce channels, and fashion revenue in Q3 2026 rose 129% year on year.

In healthcare, a subsidiary providing management support to hair-loss clinics returned to operating profit in Q3 2026, with operating profit up 170% year on year.

Consolidation also widened, as an AI-based adtech and digital healthcare company was included from June 2026 and a clinic-related company acquired by Metacare from July 2026. Another subsidiary, MetaSNC, offers CRM software for non-reimbursed clinics and is developing a global version.

In October 2026 the company signed an MOU with a Chinese surgical robotics firm on AI hair-transplant robots. In fashion, same-sector peers include Youngone, F&F, Handsome, LF and Shinsegae International. In healthcare, the company describes its model as combining clinic management support with medical IT capability.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩30B-₩200M−0.8%
2025Q4₩31.1B-₩1.1B−3.5%
2026Q1₩30.4B₩500M1.7%
2026Q2₩27.6B₩300M1.0%
2026Q3₩40.7B₩1.7B4.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩22.7B-₩2B-₩4.1B−9.0%−5.2%14.1%
2023₩21.6B-₩3.9B-₩7.3B−17.9%−10.2%52.4%
2024₩38.4B-₩3.2B₩200M−8.3%0.3%67.7%
2025₩81.3B-₩7.2B-₩8.8B−8.9%−12.6%76.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue went from KRW 22.7 billion in 2022 to KRW 21.6 billion in 2023 (down 4.7% year on year), then KRW 38.4 billion in 2024 (up 77.6%) and KRW 81.3 billion in 2025 (up 112.0%). After the 2023 low, revenue rose two years in a row from 2024 through 2025, and 2025 was the largest year of 2022–2025.

Operating losses were KRW 2.05 billion in 2022, KRW 3.86 billion in 2023, KRW 3.2 billion in 2024 and KRW 7.24 billion in 2025, a loss every year from 2022 through 2025. Operating margin was -9.0%, -17.9%, -8.3% and -8.9%, so the 2025 margin was slightly worse than 2024 even though revenue more than doubled.

Net loss attributable to controlling shareholders was KRW 4.1 billion in 2022 and KRW 7.3 billion in 2023, turned to a KRW 197 million profit in 2024, and returned to a KRW 8.79 billion loss in 2025. Net income including non-controlling interests, a different figure, was a loss of KRW 12.4 billion in 2025.

The debt ratio rose from 14.1% in 2022 to 76.2% in 2025; at end-2025 total liabilities were KRW 108.1 billion and total equity KRW 141.8 billion, of which KRW 69.9 billion belonged to controlling shareholders.

Operating cash flow was negative in each of 2023 (-KRW 49.57 million), 2024 (-KRW 3.83 billion) and 2025 (-KRW 2.5 billion), after KRW 448 million in 2022.

Quarterly, Q3 2025 revenue was KRW 30 billion with an operating loss of KRW 248 million, and Q4 2025 revenue rose to KRW 31.1 billion with a KRW 1.07 billion operating loss.

Q1 2026 revenue was KRW 30.4 billion with KRW 502 million operating profit, Q2 2026 revenue was KRW 27.6 billion with KRW 279 million, down 44.4% from the prior quarter, and Q3 2026 revenue was KRW 40.7 billion, up 35.7% year on year, with KRW 1.67 billion operating profit.

In its first-half 2026 release, the company said cost of sales fell from 89% to 84% of revenue and SG&A from 40% to 15%. Part of 2026 growth also reflects consolidation of Techlabs in June and JK Medi in July.

Attributable net results ran a KRW 242 million profit in Q3 2025, then losses of KRW 2.95 billion in Q4 2025, KRW 965 million in Q1 2026 and KRW 2.23 billion in Q2 2026, before a KRW 367 million profit in Q3 2026; the last four quarters total a KRW 5.77 billion attributable net loss.

05

Industry analysis

Metalabs straddles two end markets, so its industry read splits in two.

The fashion segment sits in apparel retail and licensing, where same-sector peers include Youngone, F&F, Handsome, LF and Shinsegae International, but the company grows through premium brand licensing and vendor operations rather than manufacturing.

In that model, which brands are brought in and which channels carry them determines revenue, and 2026 results leaned heavily on expansion in TV home shopping and live commerce. Home shopping revenue can swing with broadcast scheduling and commission terms, which is why the company also plans wider online distribution.

The healthcare segment consists of management support for hair-loss clinics and CRM and medical data software for non-reimbursed clinics. Clinic operations are shaped by domestic medical regulation, and overseas clinics and medical robotics need local regulatory approval.

Because consolidated subsidiaries have enlarged revenue, the degree of synergy among them explains results as much as the sector backdrop does. Its position against the sector average becomes visible only when set beside peers' results for the same period. The position in the cycle can be judged once industry supply and demand indicators are presented alongside.

06

Outlook

In fashion, the company said in May 2026 that it would expand premium luxury brand licensing and vendor operations and strengthen licensed apparel from overseas brands. In its November 2026 results release, it said it would diversify its brand portfolio and widen distribution channels to sustain fashion growth.

In healthcare, a subsidiary said in August 2026 that it was preparing to open, within 2026, an overseas clinic in Dubai offering hair-loss treatment and hair transplant services with a local partner.

Over the medium term the company plans to extend Korean clinic management and IT know-how into an overseas clinic operating platform.

A global version of MetaSNC's CRM software is in development, and a plan has been presented to apply it to Dubai clinics for integrated management of booking, consultation, procedure and aftercare data.

Under the October 2026 MOU with a Chinese surgical robotics firm, AI hair-transplant robot R&D, approvals and commercialization are under way. The timing of robot approvals and the scale of earnings contribution from overseas clinics have not been specified by the company.

Whether these plans translate into reported earnings is the next question, and the 2026 annual report will be the first formal full-year view of the group's profit structure.

07

Valuation

PER
—
PBR
0.3×
ROE
-7.2%
EPS
-₩211
BPS
₩3,343
Dividend per share
₩0

An earnings-based multiple cannot currently be calculated, because the last four quarters carry a combined attributable net loss of KRW 5.77 billion, so the share price cannot be measured against profit. On a book-value basis, the price-to-book ratio sits well below 1x.

Of total equity of KRW 141.8 billion at end-2025, KRW 69.9 billion belonged to controlling shareholders, and market capitalization sits below that attributable equity figure, which is the starting point for a book-value reading.

Attributable net income turned to profit in 2024, returned to a loss in 2025, and posted a profit in Q3 2026, but profit has not yet held across consecutive quarters. Cash returns to shareholders through dividends are small at the current level.

Comparison with a past earnings-based multiple band would require a run of profitable periods, so book-value comparison is the practical anchor for now. Against same-sector listed companies, book-value measures allow a more consistent comparison than earnings multiples do.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Fashion-led revenue growth

Fashion revenue in Q3 2026 rose 129% year on year, and total revenue reached KRW 81.3 billion in 2025, up 112.0% from 2024. Q3 2026 revenue of KRW 40.7 billion was up 35.7% year on year. The company attributes growth to premium brand licensing distribution expanding through TV home shopping and live commerce.

Return to operating profit

Operating profit turned positive in both Q1 2026 (KRW 502 million) and Q3 2026 (KRW 1.67 billion). In its first-half 2026 release, the company said cost of sales fell from 89% to 84% of revenue and SG&A from 40% to 15%. The healthcare subsidiary also returned to profit in Q3 2026, with operating profit up 170% year on year.

Healthcare options beyond the core

A subsidiary said in August 2026 it was preparing to open a hair-treatment clinic in Dubai within the year. In October 2026 the company signed an MOU with a Chinese medical robotics firm on AI hair-transplant robots. Both still depend on approvals and opening schedules, so they remain options rather than reported earnings.

09

Bear factors

Attributable losses over the last four quarters

Attributable net loss swung back to KRW 8.79 billion in 2025, followed by a KRW 2.95 billion loss in Q4 2025 and a KRW 2.23 billion loss in Q2 2026. The last four quarters total a KRW 5.77 billion attributable net loss. The KRW 367 million attributable profit in Q3 2026 is a single quarter.

Operating margin and cash flow

The 2025 operating margin of -8.9% was slightly worse than -8.3% in 2024, and operating losses ran four years in a row from 2022 through 2025. Operating cash flow was negative in 2023, 2024 and 2025. Q2 2026 operating profit of KRW 279 million fell 44.4% from the prior quarter.

Consolidation effects and balance sheet strain

Part of 2026 revenue growth came from consolidating Techlabs in June and JK Medi in July, which makes organic growth harder to separate. Fashion revenue depends on TV home shopping and live commerce channels. The debt ratio rose from 14.1% in 2022 to 76.2% in 2025.

10

Risk factors

Balance sheet

Total liabilities were KRW 108.1 billion at end-2025, with a debt ratio of 76.2%. Of KRW 141.8 billion in total equity, KRW 69.9 billion belongs to controlling shareholders, so non-controlling interests account for a substantial share. Continued negative operating cash flow could raise reliance on borrowing.

Channel and contract concentration

Fashion revenue relies on TV home shopping and live commerce channels. Changes to licensing terms or channel scheduling could move quarterly revenue sharply. Q2 2026 revenue fell 9.0% from the prior quarter, illustrating the quarterly volatility.

Regulation and new-business execution

The hair-loss medical business is shaped by regulation governing clinic operations. Overseas clinics and AI hair-transplant robots may slip depending on local rules and approval timing. As the number of consolidated subsidiaries grows, managing synergies and oversight becomes more demanding.

11

What to watch next

  1. End of 2026 (targeted)

    Whether the Dubai hair-loss clinic opens. The company said in August 2026 it was preparing to open within the year, so an opening would be the first signal for the overseas clinic business.

  2. End of March 2027 (annual report filing deadline)

    Full-year 2026 operating margin and attributable net result in the annual report. This is the first formal check on whether quarterly profits in 2026 carried through on a full-year basis.

  3. Mid-May 2027 (Q1 quarterly report filing deadline)

    Q1 2027 operating profit and attributable net result. This shows whether the profits of Q1 and Q3 2026 persist or whether quarterly declines like Q2 2026 recur.

12

Overall view

Metalabs' revenue reached KRW 81.3 billion in 2025, a sharp expansion, but operating and attributable net losses persisted through 2025.

In 2026, fashion growth and the return to profit at a healthcare subsidiary turned operating profit positive in Q1 and Q3, although Q2 operating profit fell and attributable net results alternated by quarter.

The KRW 5.77 billion attributable net loss over the last four quarters shows that earnings recovery has not yet accumulated. On the strength side, revenue growth, improved cost ratios and better subsidiary profitability are documented.

On the weakness side, a higher debt ratio, negative operating cash flow and possible distortion from consolidation remain. Separating consolidation effects from organic growth will require the full-year figures in the 2026 annual report.

The next checkpoint after that is whether profitability holds in the Q1 2027 quarterly report. Overseas clinics and robotics remain options whose earnings impact depends on schedules that have yet to be fixed. This report does not offer an investment opinion and presents figures and disclosure timing as information.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. view.asiae.co.kr
  2. etoday.co.kr
  3. m.etoday.co.kr
  4. supple.kr
  5. digitaltoday.co.kr
  6. supple.kr
  7. etoday.co.kr
  8. supple.kr
  9. mt.co.kr
  10. vegannews.co.kr
  11. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis